Detection of anti-neurochondrin autoantibody in patients with cerebellar ataxia or cerebellitis

Patent metadata

Field	Value
Publication number	US-10112982-B2
Application number	US-201615078361-A
Country	US
Kind code	B2
Filing date	Mar 23, 2016
Priority date	Apr 22, 2015
Publication date	Oct 30, 2018
Grant date	Oct 30, 2018

Abstract

Polypeptides including Neurochondrin and autoantibodies binding to polypeptides including Neurochondrin are provided. Methods for diagnosing or treating diseases associated with neurological symptoms or cancers are also provided. The methods of diagnosis may include detecting an autoantibody binding to Neurochondrin in a sample from a patient. The methods of treatment may include administering a polypeptide comprising Neurochondrin to a patient.

First claim

The invention claimed is:

1. A method of detecting an autoantibody to Neurochondrin in a subject, the method comprising:
contacting a bodily fluid sample isolated from a subject having cerebellar ataxia or cerebellitis with a polypeptide comprising Neurochondrin, wherein the polypeptide comprising Neurochondrin is recombinant and/or isolated, and binds specifically to autoantibodies binding to Neurochondrin, and
detecting the presence or absence of the autoantibody to Neurochondrin in a complex with the polypeptide.

2. The method of claim 1 , wherein the polypeptide is immobilized on a solid carrier.

3. The method of claim 1 , wherein the polypeptide is provided in the form of an isolated cell comprising a nucleic acid encoding the polypeptide or in the form of an isolated tissue comprising the polypeptide.

4. The method of claim 1 , wherein the subject is at least one of a human and a mammal.

5. A method of detecting a complex comprising an autoantibody bound to a polypeptide comprising Neurochondrin in a subject, the method comprising:
obtaining a bodily fluid sample from a subject, wherein the subject has cerebellar ataxia or cerebellitis,
contacting the bodily fluid sample from the subject with a polypeptide comprising Neurochondrin, wherein the polypeptide comprising Neurochondrin is recombinant and/or isolated, and binds specifically to autoantibodies binding to Neurochondrin, and
detecting whether at least one complex comprising the autoantibody bound to the polypeptide is present in the bodily fluid sample.

6. The method of claim 5 , wherein the polypeptide is immobilized on a solid carrier.

7. The method of claim 5 , wherein detecting whether at least one complex comprising an autoantibody bound to the polypeptide is present in the bodily fluid sample comprises the use of a secondary antibody.

8. The method of claim 5 , wherein detecting whether at least one complex comprising an autoantibody bound to the polypeptide is present in the bodily fluid sample comprises the use of at least one immunoassay technique selected from radioimmunoassay, western blot, line blot, enzyme-linked immunosorbent assay (ELISA), direct immunofluorescence, and indirect immunofluorescence.

9. The method of claim 5 , wherein the bodily fluid is selected from the group comprising cerebrospinal fluid, whole blood, blood serum, lymph, interstitial fluid, and saliva.

10. The method of claim 5 , wherein the polypeptide is provided in the form of an isolated cell comprising a nucleic acid encoding the polypeptide or in the form of an isolated tissue comprising the polypeptide.

11. The method of claim 5 , wherein the subject is at least one of a human and a mammal.

Assignees

• Euroimmun Medizinische Labordiagnostika Ag

Inventors

• Miske Ramona
• Scharf Madeleine
• Komorowski Lars
• Denno Yvonne
• Probst Christian
• Dettmann Inga-Madeleine
• Stöcker Winfried
• Teegen Bianca
• Melzer Nico
• Wiendl Heinz
• Meuth Sven

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P25/14

  for treating abnormal movements, e.g. chorea, dyskinesia · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61P25/16

  Anti-Parkinson drugs · CPC title

• G01N2800/2821

  Alzheimer · CPC title